A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Seong Hyun | - |
dc.contributor.author | Kim, Yoo-Jin | - |
dc.contributor.author | Lee, Je-Hwan | - |
dc.contributor.author | Kim, Yeo-Kyeoung | - |
dc.contributor.author | Kim, Soo Jeong | - |
dc.contributor.author | Park, Sung Kyu | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Kim, Hoon Gu | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Yi, Hyeon Gyu | - |
dc.contributor.author | Joo, Young-Don | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Suk Ran | - |
dc.contributor.author | Na, Sang Min | - |
dc.contributor.author | Jang, Jun Ho | - |
dc.date.accessioned | 2021-09-04T09:12:24Z | - |
dc.date.available | 2021-09-04T09:12:24Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-12-29 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/91540 | - |
dc.description.abstract | This prospective observational study evaluated the efficacy and safety of long-term decitabine treatment in patients with myelodysplastic syndrome (MDS). Decitabine 20 mg/m(2)/day was administered intravenously for 5 consecutive days every 4 weeks to MDS patients in intermediate-1 or higher International Prognostic Scoring System (IPSS) risk categories. Active antimicrobial prophylaxis was given to prevent infectious complications. Overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and time to response were evaluated, as were adverse events. The final analysis included 132 patients. IPSS risk was intermediate-2/high in 34.9% patients. The patients received a median of 5 cycles, with responders receiving a median of 8 cycles (range, 2-30). ORR was 62.9% (complete response [CR], 36; partial response [PR], 3; marrow complete response [mCR], 19; and hematologic improvement, 25). Among responders, 39% showed first response at cycle 3 or later. OS at 2 years was 60.9%, with 17% progressing to acute myeloid leukemia. PFS at 2 years was 51.0%. Patients achieving mCR showed comparable survival outcomes to those with CR/PR. With active antibiotic prophylaxis, febrile neutropenia events occurred in 61 of 1,033 (6%) cycles. Long-term decitabine treatment with antibiotic prophylaxis showed favorable outcomes in MDS patients, and mCR predicted favorable survival outcomes. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | IMPACT JOURNALS LLC | - |
dc.subject | CONVENTIONAL CARE REGIMENS | - |
dc.subject | DNA METHYLATION | - |
dc.subject | PHASE-III | - |
dc.subject | AZACITIDINE | - |
dc.subject | TRIAL | - |
dc.title | A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.identifier.doi | 10.18632/oncotarget.6242 | - |
dc.identifier.scopusid | 2-s2.0-84953373584 | - |
dc.identifier.wosid | 000369908800068 | - |
dc.identifier.bibliographicCitation | ONCOTARGET, v.6, no.42, pp.44985 - 44994 | - |
dc.relation.isPartOf | ONCOTARGET | - |
dc.citation.title | ONCOTARGET | - |
dc.citation.volume | 6 | - |
dc.citation.number | 42 | - |
dc.citation.startPage | 44985 | - |
dc.citation.endPage | 44994 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | CONVENTIONAL CARE REGIMENS | - |
dc.subject.keywordPlus | DNA METHYLATION | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | AZACITIDINE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | decitabine | - |
dc.subject.keywordAuthor | long-term treatment | - |
dc.subject.keywordAuthor | myelodysplastic syndrome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.